• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nutex Health Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    4/25/25 5:27:27 PM ET
    $NUTX
    Business Services
    Consumer Discretionary
    Get the next $NUTX alert in real time by email
    NUTEX HEALTH INC._April 25, 2025
    0001479681false00014796812025-04-252025-04-25

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): April 25, 2025

     

    NUTEX HEALTH INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    001-41346

    11-3363609

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (I.R.S. Employer
    Identification Number)

    ​

    ‎6030 S. Rice Ave, Suite C, Houston, Texas 77081

    (Address of principal executive offices) (zip code)

     

    ‎(713) 660-0557‎

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐   Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐   Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbols(s)

    Name of each exchange on which registered

    Common Stock, $0.001 par value

     NUTX

    NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Item 4.01 Changes in Registrant’s Certifying Accountant.

    (a)Resignation of Independent Registered Public Accounting Firm

    On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum LLP (“Marcum”). On April 25, 2025, Nutex Health Inc. (the “Company”) was notified by Marcum that Marcum resigned as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s Audit Committee approved the resignation.

    ​

    The audit report of Marcum on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles.

    ​

    During the fiscal years ended December 31, 2024 and 2023 and through April 25, 2025, there were no (1) “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreement in their reports on the financial statements for such years, or (2) “reportable events” (as described in Item 304(a)(1)(v) of Regulation S-K), except for the following material weaknesses in the Company’s internal control over financial reporting:

    ​

    ●The Company had ineffective design, implementation and operation of controls over logical access, program change management and vendor management:
    oappropriate restrictions that would adequately prevent users from gaining inappropriate access to the financially relevant systems.
    oIT programs and data changes affecting the Company’s financial IT applications and underlying accounting records, are identified, tested, authorized and implemented appropriately to validate that data produced by its relevant IT systems were complete and accurate. Automated process-level and manual controls that are dependent upon the information derived from such financially relevant systems were also determined to be ineffective as a result of such deficiency.
    okey third party service provider SOC reports were obtained and reviewed.
    ●Business process controls across all financial reporting processes were not effectively designed and implemented to properly address the risk of material misstatement, including controls without proper segregation of duties between preparer and reviewer and key management review controls.
    ●Ineffective design and implementation of controls over the completeness and accuracy of information included in key spreadsheets supporting the financial statements.

    ​

    The Company has provided Marcum with a copy of the foregoing disclosures it is making in this Current Report on Form 8-K prior to its filing and requested, in accordance with applicable practices, that Marcum furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made herein. Attached as Exhibit 16.1 is a copy of Marcum’s letter, dated April 25, 2025, stating that it agrees with such statements.

    ​

    (b)Engagement of New Independent Registered Public Accounting Firm

    On April 25, 2025, with the approval of the Company’s Audit Committee, CBIZ was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.

    ​

    During the fiscal years ended December 31, 2024 and 2023 and through April 25, 2025, neither the Company nor anyone on its behalf consulted with CBIZ regarding (1) the application of accounting principles to a specified transaction, completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (2) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

    ​

    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit No.

    Description of Exhibit

    16.1

    Letter from Marcum LLP dated April 25, 2025

    104

    Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

    ​

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    ​

    ​

    ​

    ​

    Date: April 25, 2025

    ​

    ​

    Nutex Health Inc.

    ​

    ​

    ​

    By: /s/ Jon C. Bates

    ​

    Jon C. Bates

    ​

    Chief Financial Officer

    ​

    ​

    ​

    ​

    ​

    ​

    Get the next $NUTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUTX

    DatePrice TargetRatingAnalyst
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    9/18/2024$45.00Buy
    Maxim Group
    2/22/2023$3.00Outperform
    Northland Capital
    More analyst ratings

    $NUTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      11/14/24 11:02:17 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Nutex Health Inc. (Amendment)

      SC 13G/A - Nutex Health, Inc. (0001479681) (Subject)

      9/26/23 4:26:07 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      7/7/23 5:03:39 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NUTEX HEALTH ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

      HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors.  They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment. The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market. Mr. Saunders will s

      4/22/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JOSHUA DETILLIO AS ITS NEW CHIEF OPERATING OFFICER

      HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023. Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in investor-owned, publicly traded companies. He has demonstrated success in collaborating with and leading boards and physicians to drive growth, improve c

      9/5/23 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JON BATES AS ITS NEW CHIEF FINANCIAL OFFICER

      HOUSTON, June 10, 2022 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, today announced the appointment of Jon Bates as the Company's Chief Financial Officer effective on or about June 30, 2022. On May 3, 2022, Michael Bowen notified the company that he intends to retire as Chief Financial Officer of the Company. In connection with Mr. Bowen's retirement, the Company's Board formed a search committee.  On June 8, 2022, the Company announced the appointme

      6/10/22 6:00:00 AM ET
      $NUTX
      $USPH
      Business Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $NUTX
    Financials

    Live finance-specific insights

    See more
    • Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

      HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com

      5/7/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, March 17, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of the stock market on March 27th, 2025. The Company will discuss those results on a conference call on Friday, March 28st, 2025, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://viavid.webcasts.com/starthere.jsp?ei=1706653&tp_key=5e3e4c2f6

      3/17/25 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 THIRD QUARTER FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691722&tp_key=bfd69ce

      11/5/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Director Spears Kelvin converted options into 143 shares and covered exercise/tax liability with 34 shares, increasing direct ownership by 0.34% to 31,992 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:15:36 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua converted options into 2,125 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 35% to 6,481 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:01:59 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    SEC Filings

    See more
    • Nutex Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Nutex Health, Inc. (0001479681) (Filer)

      5/13/25 4:31:29 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Nutex Health Inc.

      10-Q - Nutex Health, Inc. (0001479681) (Filer)

      5/13/25 4:28:53 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form 424B3 filed by Nutex Health Inc.

      424B3 - Nutex Health, Inc. (0001479681) (Filer)

      5/2/25 4:35:17 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET LOSS OF $0.4 MILLION IN Q1 2024DILUTED EPS OF $2.56 PER SHARE VERSUS $(0.08) PER SHARE IN Q1 2024EBITDA OF $43.1 MILLION VERSUS $7.1 MILLION IN EBITDA IN Q1 2024, AN INCREASE OF 507.0%ADJUSTED EBITDA OF $72.8 MILLION VERSUS $(0.4) MILLION IN Q1 2024NET CASH FROM OPERATING ACTIVITIES OF $51.0 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS HAVE RESULTED IN MORE FAIR AND REASONABLE PAYMENTSHOUSTON, May 13, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NA

      5/13/25 5:43:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

      HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com

      5/7/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      FULL YEAR 2024 HIGHLIGHTS: TOTAL REVENUE OF $479.9 MILLION VERSUS $247.6 MILLION IN 2023, AN INCREASE OF 93.8%NET INCOME OF $52.2 MILLION VERSUS NET LOSS OF $45.8 MILLION IN 2023DILUTED EPS OF $9.71 PER SHARE VERSUS $(10.39) PER SHARE IN 2023EBITDA OF $98.4 MILLION VERSUS $(22.5) MILLION IN EBITDA IN 2023ADJUSTED EBITDA OF $123.7 MILLION VERSUS $10.8 MILLION IN 2023, AN INCREASE OF 1,045.4%NET CASH FROM OPERATING ACTIVITIES OF $23.2 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS, THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS, HAS RESULTED IN MORE EQUITABLE PAYMENTSHOUSTON, March 31, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physicia

      3/31/25 4:30:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Nutex Health with a new price target

      Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

      11/12/24 8:15:57 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Maxim Group initiated coverage on Nutex Health with a new price target

      Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00

      9/18/24 8:12:45 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Northland Capital initiated coverage on Nutex Health with a new price target

      Northland Capital initiated coverage of Nutex Health with a rating of Outperform and set a new price target of $3.00

      2/22/23 9:08:40 AM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Financial Officer Bates Jon Christian bought $28,970 worth of shares (1,350 units at $21.46), increasing direct ownership by 146% to 2,277 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      8/26/24 11:54:30 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua bought $10,800 worth of shares (20,000 units at $0.54), increasing direct ownership by 214% to 29,333 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      6/13/24 11:50:03 AM ET
      $NUTX
      Business Services
      Consumer Discretionary